

Consensus Meeting Report

Development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease

2017



**World Health
Organization**

FIND

Because diagnosis matters

WHO collaborating centre for the evaluation
of new diagnostic technologies

Consensus Meeting Report

Development of a Target Product Profile (TPP)
and a framework for evaluation for a test
for predicting progression from tuberculosis infection
to active disease



2017

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Consensus meeting report: development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.18). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements iv

Participants in Technical Expert Consultation iv

Abbreviations..... vi

1. Introduction 1

2. Scope 2

3. Expert Consultation Process 3

4. The evolving concept of LTBI diagnosis 4

5. Target Product Profile: Test predicting progression from tuberculosis infection to active disease 8

6. Framework for the evaluation for tests that predict progression from tuberculosis infection to active disease..... 10

6.1 Clinical evaluation studies..... 10

6.2 Health impact studies..... 14

6.3 Summary of clinical and health impact studies..... 16

Annex 1: Target Product Profile: Test predicting progression from tuberculosis infection to active disease..... 17

Acknowledgements

This document was prepared by Alberto Matteelli (University of Brescia), Sandra Kik (KNCV), Samuel Schumacher (FIND) and Alessandra Varga (FIND), with input from Christopher Gilpin and Alexei Korobitsyn (Global TB Programme, World Health Organization) on the basis of a New Diagnostic Working Group consensus building process used to develop target product profiles (TPP) for tests that can predict progression from latent TB infection to active TB disease. The TPP was drafted by Prathiba Seshadri and Claudia Denking (FIND) and refined by Samuel Schumacher (FIND) with the input from the New Diagnostic Working Group Taskforce on LTBI and stakeholders in the field.

Participants in Technical Expert Consultation

New Diagnostic Working Group Taskforce on LTBI Members

Catharina Boehme (FIND Geneva, Switzerland); Gavin Churchyard (Aurum Institute for Health Research, Johannesburg, South Africa); Frank Cobelens (AIGHD, Amsterdam, The Netherlands); Daniela Maria Cirillo (NDWG Co-Chair, San Raffaele Research Institute, Milan, Italy); Christopher Gilpin (Global TB Programme, World Health Organization, Geneva, Switzerland); Delia Goletti (National Institute for Infectious Diseases, Rome, Italy); Christian Lienhardt (Global TB Programme, World Health Organization, Geneva, Switzerland); Alberto Matteelli (Coordinator, NDWG TF on LTBI, University of Brescia, Brescia, Italy); Dick Menzies (remotely - McGill University, Montreal, Canada); Molebogeng Rangaka (University College London, London, United Kingdom); Samuel Schumacher (FIND, Geneva, Switzerland); Alessandra Varga (Secretariat NDWG, FIND, Geneva, Switzerland)

Technical Expert Members

Helen Ayles (LSHTM/Zambart, London, United Kingdom); Pauline Beattie (EDCTP, The Netherlands); Grania Brigden (The Union, Paris, France); Hanif Esmail (University of Oxford, Oxford, United Kingdom); David Lewinsohn (Chair Working Group on New Vaccines, University of Portland, Portland, USA); Thomas Scriba (remotely- University of Cape Town, Cape Town, South Africa); Marieke van der Werf (ECDC, Stockholm, Sweden); Kevin Winthrop (remotely - Oregon HS, Portland, USA); Jean-Pierre Zellweger (Swiss Lung Association, Bern, Switzerland)

Community representatives

Ruvandhi Nathavitharana (TB Proof, South Africa); Khairunisa Suleiman (Global TB Community Advisory Board Diagnostics Workgroup, Nairobi, Kenya)

Country representatives

Norbert Ndjeka (Drug-Resistant TB, TB & HIV National Department of Health, Pretoria, South Africa); Rohit Sarin (National Institute of TB & Respiratory Diseases, New Delhi, India); Irina Vasilieva (Ministry of Health, Moscow, Russian Federation); Nguyen Viet Nhung (National TB Programme Manager, Director of National Lung Hospital, Hanoi, Vietnam)

Donor Agencies

René Becker-Burgos (Global Fund, Geneva, Switzerland); Thomas Forissier (Bill & Melinda Gates Foundation, Seattle, USA)

Diagnostic test developers (Observers)

Alexandra Asbach-Nitzsche (Lophius, Germany); Jeff Boyle (Qiagen, USA); Anke Coblenz (Abbott, USA); William Cruikshank (Oxford Immunotec, United Kingdom); Philippe Jacon (Cepheid, France); Masae Kawamura (Qiagen, USA); Oksana Markova (Generium, Russian Federation); Chris Novak (Roche, Switzerland); Morten Ruhwald (Statens Serum Institute, Denmark); Andrae Vinson (BD, USA)

WHO Secretariat (WHO Global TB Programme)

Haileyesus Getahun, Christopher Gilpin, Yohhei Hamada, Alexei Korobitsyn, Karin Weyer

Target Product Profile – External Review Group

Sunday Agbochenu Aboje (HIV/AIDS Division, Federal Ministry of Health, Nigeria); Ibrahim Abubaker (Institute for Global Health, University College London, London, United Kingdom); Mohammed Rheda Al Lawati (Consultant Physician, Oman); Peter Henrik Andersen (Statens Serum Institut, Denmark); Judith Bruchfeld (Karolinska Institute and Karolinska University Hospital, Sweden); Rolando Cedillos (Servicio de Infectología y Programa de Atención Integral en ITS/VIH/SIDA Hospital Nacional Rosales, El Salvador); Richard Chaisson (Center For Tuberculosis Research, John Hopkins University, USA); Lucy Chesire (TB Advocacy Consortium, Kenya); Ray Cho (Department of Microbiology, Yonsei University College of Medicine, Republic of Korea); Gavin Churchyard (The AURUM Institute, South Africa); Daniela Maria Cirillo (WHO Collaborating Centre and TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Italy); Thierry Comolet (Direction Générale de la Santé, lutte contre la tuberculose, Ministère du travail, de l'emploi et de la santé, France); Anand Date (Centers for Diseases Control and Prevention, USA); Gerard de Vries (KNCV Tuberculosis Foundation, The Netherlands); Claudia Denking (Foundation for Innovative New Diagnostics (FIND), Switzerland); Betina Durovni (Federal University of Rio de Janeiro, Brazil); Serge Eholie (Treichville Hospital, University of Abidjan, Côte D'Ivoire); Negussie Eyerusalem (Federal Ministry of Health, Ethiopia); Mike Frick (Treatment Action Group, USA); Samarn Futakul (Director of the Bureau of AIDS TB and STIs, Department of Disease Control, Ministry of Public Health, Thailand); Mina Gaga (Athens Chest Hospital, Greece); Un-Yeong Go (Korea Centers for Disease Control and Prevention, Republic of Korea); Stephen Graham (Center for International Child Health, University of Melbourne, Australia); Endang Budi Hastuti (National HIV AIDS and STI Programme, Ministry of Health, Indonesia); Einar Heldal (National TB Register, National Screening Services, Norway); Adeeba Kamarulzaman (University of Malaya, Malaysia); Phillipe LoBue (Centers for Disease Control and Prevention, USA); Richard Menzies (Montreal Chest Institute MUHC and McGill University, Canada); Giovanni Battista Migliori (WHO Collaborating Centre for TB and Lung Diseases, Maugeri Care and Research Institute, Italy); Beatrice Mutayoba (National Tuberculosis and Leprosy Programme, Ministry of Health, United Republic of Tanzania); Lindiwe Mvusi (National Department of Health, South Africa); Ivan Solovic (National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Slovakia); Giovanni Sotgiu (Clinical Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences, University of Sassari, Italy); Tim Sterling (Vanderbilt University School of Medicine, USA); Alistair Story (TB Screening Service Find & Treat, United Kingdom); Marieke van der Werf (European Centre for Disease Prevention and Control (ECDC), Sweden); Wim Vandeveld (Global TB Community Advisory Board, South Africa); Nguyen Van Hung (National TB Reference Laboratory, National Lung Hospital, Viet Nam); Kitty van Weezenbeek (KNCV Tuberculosis Foundation, The Hague, Netherlands); Tuula Vasankari (Finnish Lung Association, Finland); Constantia Voniatis (Clinical Laboratories, Ministry of Health, Cyprus); Maryse Wanlin (Belgian Lung and Tuberculosis Association (BELTA), Belgium); Brita Askeland Winje (Department of Infectious Disease Epidemiology, Norwegian Institute of Public Health, Norway); Takashi Yoshiyama (Research Institute of Tuberculosis, Japan).

Abbreviations

BCG	Bacille Calmette–Guérin
FIND	Foundation for Innovative New Diagnostics
HEOR	health economics and outcomes research
HI	health informatics
HIV	human immunodeficiency virus
IGRA	interferon-gamma release assays
IPT	intermittent preventive treatment
ITT	incipient TB test
LTBI	latent TB infection
MDR-TB	multidrug-resistant tuberculosis
MTB	<i>M. tuberculosis</i>
NDWG	New Diagnostics Working Group
NGO	Nongovernmental organization
NPV	negative predictive value
PIT	persistent infection test
PLHIV	Persons living with HIV
PPV	positive predictive value
PT	preventive treatment
TR	tuberculosis

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26138

